Onchocerciasis Treatment Market Report 2026

Onchocerciasis Treatment Market Overview

• Onchocerciasis Treatment market size has reached to $1.11 billion in 2025 • Expected to grow to $1.59 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Surge In Eye-related Conditions Fueling Growth Of The Market Due To Rising Risk Of Vision Loss • Market Trend: Novel Antiparasitic Medications Driving Growth In The Market Through Improved Efficacy And Access • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Onchocerciasis Treatment Market?

Onchocerciasis treatment refers to the medical and therapeutic interventions designed to manage and eliminate onchocerca volvulus infections, which cause river blindness a parasitic disease primarily affecting skin and eye health. The primary goal of treatment is to eliminate the microfilariae (immature larvae) and reduce transmission, symptoms, and the risk of vision loss. The main drug types of onchocerciasis treatment are ivermectin, doxycycline, albendazole, and moxidectin. Ivermectin is an antiparasitic medication used to treat various parasitic infections, including onchocerciasis (river blindness), by killing the larvae (microfilariae) of the parasite Onchocerca volvulus. The treatment strategies include mass drug administration (MDA) and targeted treatment, with modes of administration including oral, injectable, and topical forms. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies and are used by various end-users such as hospitals and clinics, home care settings, and government and non-governmental programs.

What Is The Onchocerciasis Treatment Market Growth Forecast?

The onchocerciasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to introduction of moxidectin and long-acting formulations, expansion of online and retail pharmacy distribution, development of combination therapies, increased government and NGO funding for eradication programs, adoption of community-based preventive strategies. Major trends in the forecast period include expansion of mass drug administration (mda) programs, development of pediatric and fixed-dose formulations, increased focus on anti-wolbachia therapies, integration of oral and injectable treatment regimens, growth of community-based and government-supported treatment campaigns.

What Are The Drivers Of The Onchocerciasis Treatment Market?

The rise in patients suffering from eye-associated issues is expected to propel the growth of the onchocerciasis treatment market going forward. Eye-associated issues refer to a variety of conditions that affect vision and ocular health, including infections, injuries, and chronic illnesses such as glaucoma or cataracts. The growth in patients suffering from eye-associated issues is primarily due to increasing screen time and prolonged exposure to digital devices. Onchocerciasis treatment helps prevent and manage vision loss and blindness in patients by eliminating the parasitic infection that causes inflammation and damage to ocular tissues. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, about 20.5 million Americans over the age of 40 have cataracts in at least one eye, accounting for 17.2% of that population. It is projected that nearly 30 million people will develop cataracts by 2028. Therefore, the rising prevalence of eye-related conditions is driving growth in the onchocerciasis treatment industry. The rising demand for surgical procedures is expected to propel the growth of the onchocerciasis treatment market going forward. Surgical procedures refer to medical interventions aimed at removing or repairing tissues damaged by disease, often used when drug treatments are ineffective or when complications threaten long-term health. This rise is driven by the progression of onchocerciasis in some patients to advanced stages, where surgical intervention becomes necessary to prevent permanent damage, such as vision loss or disfigurement. As a result, healthcare providers are expanding surgical services and investing in advanced techniques, thereby boosting the overall market for onchocerciasis treatment. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional body for board-certified aesthetic plastic surgeons, in 2023, nearly 35 million aesthetic procedures were performed worldwide, a 3.4% increase from 2022. The report also highlighted that surgical procedures rose by 5.5%, with more than 15.8 million procedures performed by plastic surgeons. Therefore, the rising demand for surgical procedures is driving growth in the onchocerciasis treatment industry.

Key Players In The Global Onchocerciasis Treatment Market

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Global Onchocerciasis Treatment Market Trends and Insights

Major companies operating in the onchocerciasis treatment market are focusing on developing novel antiparasitic medications to improve treatment effectiveness and reduce duration. Antiparasitic medications are drugs designed to eliminate or inhibit parasites such as worms and protozoa that cause infections in humans. For instance, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, received approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets to treat river blindness in individuals aged 4 years and older. This approval enables Ghana to implement community-based mass drug administration programs using moxidectin, which offers greater efficacy and longer-lasting effects compared to ivermectin. With this approval, MDGH aims to expand access to an effective new treatment for onchocerciasis, enabling large-scale community programs in endemic regions.

What Defines the Onchocerciasis Treatment Market?

The onchocerciasis treatment market consists of revenues earned by entities providing services such as mass drug administration (MDA) campaigns, community-based health outreach, disease surveillance and diagnostics, vector control initiatives, and public health education. The market value includes the value of related goods sold by the service provider or included within the service offering. The onchocerciasis treatment market also includes sales of antiparasitic drugs, diagnostic kits, drug delivery tools, and protective supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Onchocerciasis Treatment Market Report 2026?

The onchocerciasis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the onchocerciasis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.